Understanding RSV and Why It’s a‍ Threat to Seniors

Respiratory Syncytial Virus (RSV) is​ a common respiratory virus that usually causes mild, cold-like symptoms. Though, for⁣ older adults, RSV can lead ⁢to severe illness, including pneumonia and hospitalization. Before ⁣the availability of a ⁢vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths ⁣annually among adults 65 years and older in ⁢the United States.

The ‌virus spreads through close contact with infected individuals, much⁤ like the common​ cold or flu. Symptoms can‌ include a runny nose, cough, fever, and shortness of breath. Older adults are particularly vulnerable ⁣because their immune systems weaken with age, making them less able to fight‍ off the infection effectively.

The Arexvy Vaccine: How it effectively⁢ works and Trial Results

Arexvy, developed⁣ by ⁢GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein ⁢is found on the surface of the RSV virus⁣ and is crucial for ‌the virus to enter⁢ cells. By exposing the immune system to this protein, the vaccine prepares the body to recognize and fight off⁣ the virus if‌ exposed.

The approval of Arexvy is based on data from the RSVAPEX trial,a large,randomized,placebo-controlled ⁢study involving nearly 24,636 adults aged 60 years and older. The study, detailed in the December 4, 2025, issue of the New England ​Journal of Medicine, demonstrated ​a ‌vaccine⁣ efficacy⁤ of 82.6% against RSV-associated lower ⁢respiratory tract ‍disease (LRTD) with at least one symptom. Efficacy against severe LRTD, defined as requiring⁤ hospitalization, was 94.1%.

Importantly, the trial ⁤also assessed safety. ⁢ While some​ participants experienced mild side effects such as pain ‌at the injection site, fatigue, and muscle aches, serious adverse events were rare and⁤ not significantly different between the vaccine and placebo ⁤groups. A‌ small increased risk of inflammatory conditions was observed,prompting ongoing monitoring.

Who Should Get the RSV Vaccine?

The centers for Disease Control and Prevention (CDC) recommends that adults aged 60 years and older ⁣may receive a dose of RSV vaccine,based on shared clinical decision-making ‌with their healthcare provider. This means that individuals should discuss the benefits and ⁣risks of vaccination with their doctor to determine if it’s right ‍for them.

Factors to consider include individual health status, risk of RSV⁣ exposure, and personal preferences. Those with underlying medical conditions, such as⁤ heart or lung disease, may benefit particularly from vaccination. Though, individuals with a history of certain⁤ autoimmune conditions should consult ​their ‍doctor before receiving‍ the vaccine.

Timeline‍ of RSV Vaccine Development ‌and Approval